



















































Guidelines Guidelines Clinical focusClinical practice guidelines for dementia
in AustraliaSummaryementia is a National Health Priority Area in
Australia. As our population ages, the number of  About 9% of Australians aged 65 years and over
have a diagnosis of dementia.
 Clinical practice guidelines aim to enhance research
translation by synthesising recent evidence for health
and aged care professionals.
 New clinical practice guidelines and principles of care
for people with dementia detail the optimal diagnosis
and management in community, residential and
hospital settings. The guidelines have been approved
by the National Health and Medical Research
Council.
 The guidelines emphasise timely diagnosis; living well
with dementia and delaying functional decline;
managing symptoms through training staff in how to
provide person-centred care and using non-
pharmacological approaches in the first instance;
and training and supporting families and carers to
provide care.Dpeople with dementia will increase.1 People with
dementia have deficits in one or more of the areas of
memory, communication, attention, thinking and
judgement.2
The quality of clinical practice in dementia care in
Australia is variable. The availability of high-quality ser-
vices to support workforce training, diagnosis and
ongoing care, advance care planning and support for
families to provide care is inconsistent.
Clinical practice guidelines can improve uptake of
research findings by identifying, synthesising and
disseminating evidence to clinicians.3 Most importantly,
adherence to clinical practice guidelines can improve the
quality and consistency of care.4
The National Health and Medical Research Council
(NHMRC) Partnership Centre forDealingwith Cognitive
and Related Functional Decline in Older People was
established in 2013 with funding support from the
NHMRC, HammondCare, Alzheimer’s Australia,
Brightwater Care Group and Helping Hand Aged Care.
One of the activities of the Partnership Centre was to
develop Australian clinical practice guidelines for de-
mentia. The guidelines were adapted from existing
guidelines5 using ADAPTE methodology6 to reflect the
Australian context and the latest evidence. A multidisci-
plinary guideline committee, which included consumers,
was appointed to refine the scope of the guidelines and
form recommendations based on systematic reviews of
the evidence.
The purpose of the guidelines is to provide recommen-
dations for an agreed standard of practice for the diag-
nosis and management of people with dementia in
Australia. The guidelines address care of people with
dementia in community, residential care and hospital
settings and are relevant to medical practitioners, nurses,
aged care workers and allied health professionals. They
are also useful for researchers, educators, policy makers
and decision makers.
The full guidelines can be accessed via the Australian
Clinical Practice Guidelines portal (https://www.
clinicalguidelines.gov.au).
Main recommendations
The guidelines provide 109 recommendations, cat-
egorised as evidence-based recommendations (formu-
lated after a systematic review of the evidence),
consensus-based recommendations (formed where a
systematic review has failed to identify sufficient studies
to inform a recommendation) and practice points (basedon expert opinion). Key recommendations prioritised by
the committee for implementation are presented in the
Box.
Changes in management
Delays between the onset of symptoms and diagnosis of
dementia are widely acknowledged.7 There is currently a
lack of information regarding the benefits and harms of
population screening for cognitive impairment.8 The
guidelines focus on timely diagnosis by recommending
that symptoms are explored when first raised by the
person experiencing the symptoms and/or their carer or
family and are not dismissed as “just a part of ageing”.
People with a possible diagnosis of dementia should be
referred to a service or specialist in dementia diagnosis
(eg, a memory clinic, neurologist, geriatrician or
psychiatrist).9
The guidelines recommend a systematic approach to
diagnosing dementia; this includes patient and informant
history taking, cognitive assessment, medication review,
blood tests and computed tomography or magnetic
resonance imaging to exclude other cerebral pathologies.
Theuse of single-photon emission computed tomography
is not recommended.10More recent diagnostic techniques
using biomarkers (including the use of positron emission
tomography) are not recommended for routine use.11
Clinical cognitive assessment should include examination
with a screening tool with established reliability and
validity. A number of tools are recommended in the
guidelines including the Mini-Mental State Examination.
The Kimberley Indigenous Cognitive Assessment tool forMJA 204 (5) j 21 March 2016 1
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Clinical focus Guidelinesremote living Aboriginal and Torres Strait Islander pop-
ulations and the Rowland Universal Dementia Assess-
ment Scale for people from non-English speaking
backgrounds are recommended for use where illiteracy,
language or cultural considerations deem their use
appropriate.
The committee recommended review of peoplewithmild
cognitive impairment after 6e18 months. This recom-
mendation was formulated based on an existing system-
atic reviewwhich found that, in a clinic setting, the annual
conversion rate of mild cognitive impairment to Alz-
heimer disease was close to 10%.12
At the time of diagnosis of dementia, and at regular in-
tervals subsequently, assessment should be made for
medical comorbidities and key psychiatric features asso-
ciated with dementia, including depression, to ensure
optimal management of coexisting conditions.
The guidelines recommend comprehensive role-
appropriate dementia-specific training for health and
aged care professionals. Such training can improve the
quality of life for the person with dementia13 and reduce
restraint use14,15 by teaching staff how to understand a
person with dementia and to read body language and
behaviour as signs of communication and respond
appropriately. The evidence supports training models
that focus on understanding symptoms and behaviours
and providing person-centred care.16
The guidelines recommend a greater emphasis on pro-
moting andmaintaining independence through activities
of daily living, continuing exercise and supporting the
person to pursue activities that are meaningful and of
interest to them. Adequate nourishment and hydration
through maintaining a healthy, balanced diet should be
encouraged and supported. Peoplewith dementia should
have their weight monitored and nutritional status
assessed regularly. Oral health is important17 and, on
diagnosis, the medical practitioner should recommend
that the person with dementia (or their carer[s] or family)
make an appointment to see a dentist to conduct an
assessment and formulate a long-term treatment plan.
Acetylcholinesterase inhibitors and memantine are
routinely prescribed for people with mild to moderate
Alzheimer disease in order to delay functional decline,
and the guidelines support their use.18 Based on recent
evidence, theguidelines also state that anyoneof the three
acetylcholinesterase inhibitors (donepezil, galantamine
or rivastigmine) could also be considered for people with
dementiawith Lewy bodies, Parkinson disease dementia,
vascular dementia or mixed dementia.19-22 The combi-
nation of an acetylcholinesterase inhibitor and mem-
antine couldbe considered formanaging the symptomsof
functional decline for people with moderate to severe
Alzheimer disease.23 Clinicians should be aware that
not all of these indications are reimbursed under the
Pharmaceutical Benefits Scheme and that acetylcholines-
terase inhibitors are associated with a number of side
effects including (but not limited to) nausea, vomiting,
diarrhoea, dizziness, increased urinary frequency, falls,2 MJA 204 (5) j 21 March 2016muscle cramps, weight loss, anorexia, headache and
insomnia.24 Acetylcholinesterase inhibitors should not be
prescribed for people with mild cognitive impairment.25
If people with dementia cannot express their needs
through communication, theymaycommunicate through
their actions and behaviour. The guidelines recommend
the need to understand the person and symptoms via a
comprehensive assessment and analysis of the behaviour
(eg, antecedent [triggers], behaviour description and
consequence [ABC approach]). The objective measure-
ment of behavioural and psychological symptoms of de-
mentia should be undertaken using tools to monitor the
type and patterns of behaviours. The provision of care
that is consistent with the ten principles of dignity in
care26 and non-pharmacological interventions should be
implemented before considering use of medications.
Non-pharmacological interventions should ideally
involve engagement in activities that are enjoyable for the
person with dementia and individualised support.
Working with the carer and family to build skills in
managing symptoms, communicating effectively and
problem solving have been shown to be effective in
reducing symptoms.27,28
A number of pharmacological treatments are recom-
mended to complement non-pharmacological ap-
proaches when the person with dementia is severely
distressed or there is an immediate risk of harm. Anal-
gesics are recommendedwhen pain is suspected.29 A trial
of selective serotonin reuptake inhibitors is recommended
for agitation; the strongest evidence is for citalopram.30
The role of antidepressants in the treatment of depres-
sion in people with dementia is uncertain. Larger trials
conducted in people with dementia have not shown
benefit (in group data) for antidepressants for treatment
of depression per se.31 Nevertheless, the committee
considered that those with a pre-existing history of major
depression (before developing dementia) who develop a
comorbidmajor depression should be treated in the usual
way.
People with Alzheimer disease, vascular dementia or
mixed dementias with mild to moderate behavioural and
psychological symptoms of dementia should not usually
be prescribed antipsychotic medications, owing to the
increased risk of cerebrovascular adverse events and
death.32 For people with severe symptoms who are dis-
tressed or causing distress to others, treatment with an
antipsychotic may be offered following a full discussion
with the person with dementia and/or their carer(s) or
family about the possible benefits and harms. Treatment
should be reviewed every 4e12 weeks, considering the
need for antipsychotics and possible cessation of
medication.
Care for people with advanced dementia should be based
on a palliative approach and involve a palliative care
service if indicated. Treatment and care should be pro-
vided as per the person’s advance care plan.
Carers and families should be included in the planning,
decision making and care and management of people
Key recommendations identified by the committee as priorities for implementation*
 Health and aged care professionals should provide person-centred care, by identifying and responding to the individual needs and preferences of
the person with dementia, their carer(s) and family. The 10 principles of dignity in care (http:/www.dignityincare.org.uk) should be used as the
standard by which care is delivered and evaluated.
 People with a possible diagnosis of dementia should be offered referral to memory assessment specialists or services for a comprehensive assessment.
 The medical practitioner should be honest and respectful and use a gradual and individualised approach when communicating the diagnosis
to the person with dementia and their carer(s) and family.
 Health system planners should ensure that people with dementia have access to a care coordinator who can work with them and their carers
and families from the time of diagnosis.*
 Health and aged care organisations should ensure that all staff working with people with dementia receive dementia-care training (attitude,
knowledge and skill development) that is consistent with their roles and responsibilities. Training should reflect programs that have been shown
to optimise care for people with dementia.*
 Training programs should be comprehensive and have a strong focus on communicating effectively with the person with dementia and his or her
carer(s) and family and recognising, preventing and managing behavioural and psychological symptoms of dementia. Staff should be trained in the
principles of person-centred care and how these principles are applied in practice.
 People with dementia living in the community should be offered occupational therapy interventions which should include: environmental
assessment and modification to aid independent functioning; prescription of assistive technology; and tailored intervention to promote independence
in activities of daily living.*
 People with dementia who develop behavioural and psychological symptoms should be offered a comprehensive assessment at an early opportunity
by a professional skilled in symptom assessment and management. This should involve their carer(s) and families as appropriate and include;
analysis of the behaviours, assessment of physical and mental health, pain or discomfort, side effects of medication, the influence of religious and
spiritual beliefs and cultural norms, physical environmental and interpersonal factors, an assessment of carer(s) health and communication style,
understanding the behaviour as a form of communication.*
 People with Alzheimer’s disease, vascular dementia or mixed dementias with mild-to-moderate behavioural and psychological symptoms of
dementia should not usually be prescribed antipsychotic medications because of the increased risk of cerebrovascular adverse events and death.
 The person with dementia, their carer(s) and family should be offered respite appropriate to their needs.
 Carers and families should have access to programs designed to provide support and optimise their ability to provide care for the person with
dementia. Programs should be individualised, multifaceted and delivered over multiple sessions.*
*Note that some recommendations have been shortened in this publication. u
Guidelines Clinical focuswith dementia. Carers are often not provided with
enough support or adequate training to effectively pro-
vide care.33 There is evidence that tailored multifaceted
programs involving both the carer and the person with
dementia can improve quality of life for both.34 Carers
should have access to programs that include education
regarding dementia; information regarding relevant ser-
vices such as respite; information about support organi-
sations such asAlzheimer’sAustralia; individualised care
management strategies to overcome specific problems;training in providing care and communicating most
effectively with the person with dementia; and support
regarding coping strategies to maintain their own well-
being, including stress management.
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